Literature DB >> 12661142

Toxoplasmosis in pregnancy is still an open subject.

Pantaleo Greco1, Antonella Vimercati, Maria Cristina Angelici, Sergio Carbonara, Grazia Doria, Luigi Nappi, Giuseppe Angarano, Luigi Selvaggi.   

Abstract

OBJECTIVE: To assess the consequences of a systematic screening for toxoplasma infection in pregnant women in a potentially high risk population.
METHODS: We have investigated all consecutive women with likely toxoplasma seroconversion in a referral center setting. Data were obtained from 68 women for whom an acute infection during pregnancy was considered likely or definite. They were all treated with antibiotics in the first instance and offered, if in the first or second trimester, amniocentesis for detection of vertical transmission (PCR and IFAT). Third trimester seroconversions and positive cases after amniocentesis were offered more aggressive antibiotic treatment.
RESULTS: Five fetuses/neonates (7%) were found to be infected. Four of them were diagnosed prenatally at amniocentesis, two women decided for termination of pregnancy, two were treated and gave birth to seronegative, normally developing children. One case was found postnatally, after a third trimester conversion; this developed into hydrocephalus with neurologic impairment. DISCUSSION: Prenatal screening and antibiotic treatment of mothers infected with toxoplasmosis showed good feasibility in our infection-susceptible population. However, there were some weak points; for example, the high number of invasive procedures and the questionable prevention of mother to child transmission in the second to third trimester.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12661142     DOI: 10.1515/JPM.2003.005

Source DB:  PubMed          Journal:  J Perinat Med        ISSN: 0300-5577            Impact factor:   1.901


  1 in total

1.  Polymerase chain reaction for detection of Toxoplasma gondii in human biological samples.

Authors:  Z Cermáková; O Rysková; L Plísková
Journal:  Folia Microbiol (Praha)       Date:  2005       Impact factor: 2.099

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.